Amarin Corporation plc: New REDUCE-IT Data Show VASCEPA/VAZKEPA (icosapent ethyl) Reduced STEMI as Well as Other MI Subtypes

-- Late-Breaking Data Show VASCEPA/VAZKEPA Significantly Reduced STEMI by 40% and NSTEMI by 27% in Pre-Specified, Post Hoc Analyses -- -- Data Presented During Late-Breaking Science Session at European

Related Keywords

Germany , United States , New Jersey , United Kingdom , Lebanon , United Arab Emirates , Ireland , Canada , Dublin , Spain , Switzerland , Barcelona , Comunidad Autonoma De Cataluna , Scotland , Great Britain , American , Clin Cardiol , Coll Cardiol , Pabout Amarin , Deepakl Bhatt , American Heart Association , Drug Administration , Science Session At European Society Of Cardiology , Professor Of Medicine At Harvard Medical School , Nasdaq , Exchange Commission , Clinical Endpoint Committee , Amarin Corporation , Journal Of The American College Cardiology , European Union , European Society Of Cardiology , Amarin Pharmaceuticals Ireland , A Report From The American Heart Association , Breaking Data Show , Post Hoc , Presented During Late Breaking Science Session , European Society , Late Breaking Science Session , Executive Director , Interventional Cardiovascular Programs , Harvard Medical School , Clinical Endpoint , New England Journal , American College , United Arab , Great Britain Marketing Authorization , Private Securities Litigation Reform Act , Securities Act , Heart Disease , Report From , American Heart , Cardiovascular Events , Icosapent Ethyl Intervention , Cardiovascular Risk Reduction , Icosapent Ethyl , Total Ischemic Events , Amarin , Corporation , Educe , Data , Show , Vascepa , Vazkepa , Icosapent , Methyl , Educed , Fatemi , Fell , Mother , Subtypes ,